Key result
Ticlopidine administered at 500 mg daily was judged superior to the 300 mg daily dose for treating ischemic ulcers due to chronic arterial occlusion, achieving a 68.5% usefulness rate.
Why the study?
Does ticlopidine 500 mg daily improve ischemic ulcers compared to 300 mg daily in patients with chronic arterial occlusion?
Does ticlopidine 500 mg daily improve ischemic ulcers compared to 300 mg daily in patients with chronic arterial occlusion?
Ticlopidine 500 mg daily appears effective and superior to 300 mg daily for treating ischemic ulcers and severe pain in patients with chronic arterial occlusion.
May support 500 mg ticlopidine for ischemic ulcers; hypothesis-generating and requires RCT confirmation before practice change.
Ticlpidine, a new inhibitor of platelet aggregation, has been administered to 80 patients with ischemic ulcer due to chronic arterial occlusion, at daily dosis of 300mg or 500mg orally for 6 weeks. Overall judgement on its usefullness revealed that daily 500mg of the drug is superior to 300mg daily dose in the treatment of ulcer. Administration with 500mg daily dose of ticlopidine were judged as useful for the treatment of ischemic ulcer. Ticlopidine was also found to be effective in improving severe pain without showing any serious side effects. In this regard, the drug can be characterized as an useful drug for the treatment of severe ischemic ulcer due to chronic arterial occlusion.Based on the pharmacological property of ticlopidine, inhibition on platelet adhesion and aggregation, it is speculated that enhanced platelet function may be closely correlated to the aggravation of these occlusive diseases.
No takes yet. Share an insight, caveat, or question.
Katsumura et al. (1980) studied Ischemic ulcer due to chronic arterial occlusion (n=80). Ticlopidine vs. 300 mg daily was evaluated on Overall usefulness for the treatment of ischemic ulcer (rated as slightly useful or better). Ticlopidine administered at 500 mg daily was judged superior to the 300 mg daily dose for treating ischemic ulcers due to chronic arterial occlusion, achieving a 68.5% usefulness rate.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: